Keywords: olmetec, first, arb, show, sclerotic, regress, japanese

Olmetec first ARB to show sclerotic regress

Article | 17 December 2007

Print This

Japanese drugmaker Daiichi Sankyo says that its angiotensin II receptor blocker Olmetec (olmesartan medoxomil), which is licensed in the UK ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in